Lead Product(s): ASC42
Therapeutic Area: Infections and Infectious Diseases Product Name: ASC42
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2021
ASC42 is an in-house developed, selective, potent farnesoid X receptor (FXR) agonist. ASC42 is an oral tablet formulation developed with in-house proprietary technology and is stable at room temperature.
Lead Product(s): mRNA Covid-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Vaccine
Partner/Sponsor/Collaborator: Sequoia Capital
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Financing June 03, 2021
Stemirna Therapeutics raised nearly $200 million to speed up the clinical study of its COVID-19 vaccine candidate, SW-0123. It is in phase I study in China and preclinical data have been published in Nature.